294 related articles for article (PubMed ID: 20714888)
1. Genetic variants affecting incretin sensitivity and incretin secretion.
Müssig K; Staiger H; Machicao F; Häring HU; Fritsche A
Diabetologia; 2010 Nov; 53(11):2289-97. PubMed ID: 20714888
[TBL] [Abstract][Full Text] [Related]
2. Two incretin hormones GLP-1 and GIP: comparison of their actions in insulin secretion and β cell preservation.
Yabe D; Seino Y
Prog Biophys Mol Biol; 2011 Nov; 107(2):248-56. PubMed ID: 21820006
[TBL] [Abstract][Full Text] [Related]
3. GIP: no longer the neglected incretin twin?
Kulkarni RN
Sci Transl Med; 2010 Sep; 2(49):49ps47. PubMed ID: 20844284
[TBL] [Abstract][Full Text] [Related]
4. Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function?
Meier JJ; Nauck MA
Diabetes; 2010 May; 59(5):1117-25. PubMed ID: 20427697
[No Abstract] [Full Text] [Related]
5. Incretins and the development of type 2 diabetes.
Meier JJ; Nauck MA
Curr Diab Rep; 2006 Jun; 6(3):194-201. PubMed ID: 16898571
[TBL] [Abstract][Full Text] [Related]
6. Effects of chronic exposure of clonal β-cells to elevated glucose and free fatty acids on incretin receptor gene expression and secretory responses to GIP and GLP-1.
Pathak V; Vasu S; Flatt PR; Irwin N
Diabetes Obes Metab; 2014 Apr; 16(4):357-65. PubMed ID: 24164718
[TBL] [Abstract][Full Text] [Related]
7. Genetic determinants of circulating GIP and GLP-1 concentrations.
Almgren P; Lindqvist A; Krus U; Hakaste L; Ottosson-Laakso E; Asplund O; Sonestedt E; Prasad RB; Laurila E; Orho-Melander M; Melander O; Tuomi T; Holst JJ; Nilsson PM; Wierup N; Groop L; Ahlqvist E
JCI Insight; 2017 Nov; 2(21):. PubMed ID: 29093273
[TBL] [Abstract][Full Text] [Related]
8. The role of incretin on diabetes mellitus.
Sanusi H
Acta Med Indones; 2009 Oct; 41(4):205-12. PubMed ID: 20737753
[TBL] [Abstract][Full Text] [Related]
9. Impaired beta cell sensitivity to incretins in type 2 diabetes is insufficiently compensated by higher incretin response.
Tura A; Bagger JI; Ferrannini E; Holst JJ; Knop FK; Vilsbøll T; Mari A
Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1123-1129. PubMed ID: 29162361
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Type 2 Diabetes and Obesity on the Basis of the Incretin System: The 2021 Banting Medal for Scientific Achievement Award Lecture.
Holst JJ
Diabetes; 2021 Nov; 70(11):2468-2475. PubMed ID: 34711671
[TBL] [Abstract][Full Text] [Related]
11. Physiology of incretins and loss of incretin effect in type 2 diabetes and obesity.
Opinto G; Natalicchio A; Marchetti P
Arch Physiol Biochem; 2013 Oct; 119(4):170-8. PubMed ID: 23859800
[TBL] [Abstract][Full Text] [Related]
12. Incretin dysfunction in type 2 diabetes: clinical impact and future perspectives.
Ahrén B
Diabetes Metab; 2013 May; 39(3):195-201. PubMed ID: 23643349
[TBL] [Abstract][Full Text] [Related]
13. Effects of acute NEFA manipulation on incretin-induced insulin secretion in participants with and without type 2 diabetes.
Astiarraga B; Chueire VB; Souza AL; Pereira-Moreira R; Monte Alegre S; Natali A; Tura A; Mari A; Ferrannini E; Muscelli E
Diabetologia; 2018 Aug; 61(8):1829-1837. PubMed ID: 29732475
[TBL] [Abstract][Full Text] [Related]
14. Impaired incretin-induced amplification of insulin secretion after glucose homeostatic dysregulation in healthy subjects.
Hansen KB; Vilsbøll T; Bagger JI; Holst JJ; Knop FK
J Clin Endocrinol Metab; 2012 Apr; 97(4):1363-70. PubMed ID: 22319034
[TBL] [Abstract][Full Text] [Related]
15. Novel extrapancreatic effects of incretin.
Yamada Y; Tsukiyama K; Sato T; Shimizu T; Fujita H; Narita T
J Diabetes Investig; 2016 Apr; 7 Suppl 1(Suppl 1):76-9. PubMed ID: 27186360
[TBL] [Abstract][Full Text] [Related]
16. Enteroinsular signaling: perspectives on the role of the gastrointestinal hormones glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide in normal and abnormal glucose metabolism.
Vahl T; D'Alessio D
Curr Opin Clin Nutr Metab Care; 2003 Jul; 6(4):461-8. PubMed ID: 12806222
[TBL] [Abstract][Full Text] [Related]
17. The incretin system and its role in type 2 diabetes mellitus.
Holst JJ; Vilsbøll T; Deacon CF
Mol Cell Endocrinol; 2009 Jan; 297(1-2):127-36. PubMed ID: 18786605
[TBL] [Abstract][Full Text] [Related]
18. Incretin actions beyond the pancreas: lessons from knockout mice.
Yabe D; Seino Y
Curr Opin Pharmacol; 2013 Dec; 13(6):946-53. PubMed ID: 24095602
[TBL] [Abstract][Full Text] [Related]
19. Noncanonical activation of Akt/protein kinase B in {beta}-cells by the incretin hormone glucose-dependent insulinotropic polypeptide.
Widenmaier SB; Sampaio AV; Underhill TM; McIntosh CH
J Biol Chem; 2009 Apr; 284(16):10764-73. PubMed ID: 19233842
[TBL] [Abstract][Full Text] [Related]
20. Incretin-based therapy of type 2 diabetes mellitus.
Knop FK; Vilsbøll T; Holst JJ
Curr Protein Pept Sci; 2009 Feb; 10(1):46-55. PubMed ID: 19275672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
